Drugs / ABvac40
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03113812 | Jan 2014 → Jul 2015 | Alzheimer disease | Araclon Biotech S.L. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03461276 | Dec 2017 → Mar 2023 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Araclon Biotech S.L. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Grifols Therapeutics LLC | Results Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s vaccine at CTAD grifols.com ↗
Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial ( NCT03461276 ) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD). |
| 2022-03-15 | Grifols Therapeutics LLC | Results Araclon Biotech advances in its innovative vaccine and diagnostic test for Alzheimer’s grifols.com ↗
Regarding the vaccine ABvac40, the principal data analyzed until now (Part A) are satisfactory in that they support the continuation of the trial’s extension phase (Part B). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Grifols Therapeutics LLC | Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s vaccine at CTAD grifols.com ↗ |
| 2023-10-24 | Grifols Therapeutics LLC | Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s vaccine at CTAD grifols.com ↗ |
| 2022-03-15 | Grifols Therapeutics LLC | Araclon Biotech advances in its innovative vaccine and diagnostic test for Alzheimer’s grifols.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABvac40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03113812 ↗ |
| Modality | Vaccine | “We have developed the first active vaccine against the C-terminal end of Aβ40, ABvac40, and assessed its safety and tolerability in a phase I clinical trial.” PMID 29378651 ↗ Jan 2018 |
| Route | Subcutaneous | “All treatments were administered subcutaneously at 4-week intervals.” PMID 29378651 ↗ Jan 2018 |